| Small to Medium sized Drug Discovery companies face several challenges when it comes to Target Discovery and Validation
The key challenges that this segment faces are:
- Lack of adequate Clinical Data for Statistical Significance
- The need to perform in silico prototyping and screening to accelerate discovery and minimize expenses
- Non-availability of full range of genomic platforms for Expression Studies during Target Discovery: eg. Microarray, qPCR, Gene Expression Profiling and Genotyping platforms
- Non-availability of full range of genomic platforms for Expression Studies during Target Validation: RNAi, Cell Lines, Cell Based Studies etc.
|